Analysis Metabolite Name Measured Value Units Cell Type:HAHA | Stimulation
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-17137Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-21991Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-22129Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-26779Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-31186Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-31871Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-36699Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-39059Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-41193Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-43334Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-46070Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-51356Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-54171Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-70724Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+CL)-Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-22288Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-23441Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-30226Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-44560Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-55107Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-64960Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-75358Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-76738Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M-H)-Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-1565Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-5268Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-34440Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-50935Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-52445Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-54489Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-64164Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaIFN-G
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaIL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaTNF-alpha
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaTNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaUntreated
Reversed phase NEGATIVE ION MODEURIDINE (CAS# 58-96-8); (M+HCOO)-Peak areaIFN-G

Return to search page
  logo